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Hepatic Iron Concentration Correlates
With Insulin Sensitivity in Nonalcoholic
Fatty Liver Disease
Laurence Britton,1-4 Kim Bridle,1,2 Janske Reiling,1,2,5 Nishreen Santrampurwala,1,2,4 Leesa Wockner,4 Helena Ching,6
Katherine Stuart,1,3 V. Nathan Subramaniam ,4,7 Gary Jeffrey,6,8 Tim St. Pierre ,9 Michael House,9 Joel Gummer,10
Robert Trengove,10 John Olynyk ,11,12 Darrell Crawford,1,2 and Leon Adams6,8
Rodent and cell-culture models support a role for iron-related adipokine dysregulation and insulin resistance in the patho-
genesis of nonalcoholic fatty liver disease (NAFLD); however, substantial human data are lacking. We examined the rela-
tionship between measures of iron status, adipokines, and insulin resistance in patients with NAFLD in the presence and
absence of venesection. This study forms part of the Impact of Iron on Insulin Resistance and Liver Histology in Nonal-
coholic Steatohepatitis (IIRON2) study, a prospective randomized controlled trial of venesection for adults with NAFLD.
Paired serum samples at baseline and 6 months (end of treatment) in controls (n 5 28) and patients who had venesection
(n 5 23) were assayed for adiponectin, leptin, resistin, retinol binding protein-4, tumor necrosis factor a, and interleukin-
6, using a Quantibody, customized, multiplexed enzyme-linked immunosorbent assay array. Hepatic iron concentration
(HIC) was determined using MR FerriScan. Unexpectedly, analysis revealed a significant positive correlation between
baseline serum adiponectin concentration and HIC, which strengthened after correction for age, sex, and body mass index
(rho 5 0.36; P 5 0.007). In addition, there were significant inverse correlations between HIC and measures of insulin
resistance (adipose tissue insulin resistance (Adipo-IR), serum insulin, serum glucose, homeostasis model assessment of
insulin resistance, hemoglobin A1c, and hepatic steatosis), whereas a positive correlation was noted with the insulin sensi-
tivity index. Changes in serum adipokines over 6 months did not differ between the control and venesection groups. Con-
clusion: HIC positively correlates with serum adiponectin and insulin sensitivity in patients with NAFLD. Further study is
required to establish causality and mechanistic explanations for these associations and their relevance in the pathogenesis
of insulin resistance and NAFLD. (Hepatology Communications 2018;2:644-653)
The epidemic of obesity in both the developedand developing world has led to a major rise inthe prevalence of nonalcoholic fatty liver dis-
ease (NAFLD). NAFLD is estimated to be present in
20%-30% of the adult population.(1) Nonalcoholic
steatohepatitis, the aggressive form of NAFLD, pre-
disposes individuals toward liver failure and hepatocel-
lular carcinoma.(2) Furthermore, NAFLD has been
Abbreviations: Adipo-IR, adipose tissue insulin resistance; BMI, body mass index; ELISA, enzyme-linked immunosorbent assay; HbA1C, hemoglobin
A1c; HIC, hepatic iron concentration; HOMA-IR, homeostatic model assessment of insulin resistance; IL-6, interleukin-6; ISI, insulin sensitivity index;
MRI, magnetic resonance imaging; NAFLD, nonalcoholic fatty liver disease; RBP-4, retinol binding protein-4; TNFa, tumor necrosis factor alpha.
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shown to be an independent risk factor for cardiovas-
cular disease and type II diabetes.(3)
Unfortunately, currently available treatment options
for NAFLD are largely ineffective, and novel thera-
peutic targets are urgently needed for this disease. Iron
has long been considered to have a role in the patho-
genesis of NAFLD and insulin resistance, a hallmark
feature of NAFLD.(4-6) Therefore, iron has been con-
sidered as a potential therapeutic target in NAFLD
and type 2 diabetes mellitus.(5,6)
In recent years, there has been considerable interest
in the role of iron in adipose tissue biology and the reg-
ulation of adipokines.(5,7) Adipokines are defined as
“polypeptides that are secreted in the adipose tissue in
a regulated manner.”(8) Many of these adipokines have
endocrine effects on the liver as well as local effects on
adipose tissue.(8) Altered adipose tissue biology and
dysregulation of adipokine synthesis may promote liver
injury by increased insulin resistance and also by other
direct and indirect effects on hepatic and adipose tissue
lipid metabolism.(8) Studies in animals and tissue cul-
ture models have demonstrated an iron-induced dysre-
gulation of the synthesis of three adipokines with such
roles, namely adiponectin, leptin, and resistin.(9-11)
Adiponectin is the most abundant adipokine in
serum and has a number of hepatoprotective effects in
NAFLD.(7,8) Iron has been shown to down-regulate
adiponectin in a rodent model of selective adipocyte
iron loading and also in cultured 3T3-L1 pre-adipo-
cytes through decreased acetylation of the transcription
factor forkhead box protein O1 (FOX01).(9) More
recently, it has been demonstrated that iron down-
regulates the appetite-suppressing hormone leptin in
mice fed a high iron diet through iron-dependent acti-
vation of cyclic adenosine monophosphate responsive
element-binding protein.(10) Two other adipokines,
resistin and retinol binding protein-4 (RBP-4), have
been associated with insulin resistance,(8) and iron has
been proposed as a regulator of serum concentrations
of both these hormones.(11,12) Tumor necrosis factor a
(TNFa) and interleukin-6 (IL-6) are cytokines
secreted from adipose tissue as adipokines as well as
from other tissues.(8) Both have important roles in the
induction of insulin resistance in NAFLD and type II
diabetes,(8,13,14) and iron has been shown in cell culture
studies to promote a proinflammatory phenotype in
macrophages.(15)
To date, studies regarding iron and the regulation of
adipokines in humans are relatively sparse. Recently, a
randomized controlled trial of 274 adults with dysme-
tabolic iron overload syndrome showed that venesec-
tion did not affect serum adiponectin levels; however,
other adipokines were not assessed.(16) Venesection in
a cohort of 6 patients with type 2 diabetes led to a
reduction in serum levels of RBP-4.(12)
At present, therefore, there is a clear need for more
comprehensive human data to determine whether the
iron–adipokine interactions observed in animal studies
might translate to humans. We hypothesized that iron
is a key determinant in the regulation of insulin sensi-
tivity and a number of adipokines relevant to NAFLD
pathogenesis. To investigate these relationships fur-
ther, we analyzed the relationships between hepatic
iron concentration and serum ferritin with markers of
insulin resistance and serum concentrations of six tar-
get adipokines. We also assessed the effect of iron
removal by venesection on serum levels of these
adipokines.
The Impact of Iron on Insulin Resistance and Liver
Histology in Nonalcoholic Steatohepatitis (IIRON2)
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study is a multicenter, prospective, randomized, con-
trolled trial evaluating the effect of venesection on liver
injury in adults with NAFLD.(17) As a component of
this larger study, this report describes the relationships
between baseline iron loading and measures of insulin
resistance as well as the effect of venesection plus life-
style advice versus lifestyle advice alone on serum con-




Subjects were recruited from hepatology clinics at the
Sir Charles Gairdner and Fremantle Hospitals in West-
ern Australia and Greenslopes Private Hospital, Queens-
land, between November 2010 and December 2012 by
the physicians involved in the study (L.A., J.O., D.C.,
and K.S.).(17) Subjects were adults with hepatic steatosis
evident on ultrasonography or computed tomography
scan and serum ferritin >50 ng/mL. Exclusion criteria
included the presence of a human factors engineering-
hemochromatosis genotype (C282Y/C282Y or C282Y/
H63D), liver disease other than NAFLD, ischemic heart
disease, uncontrolled diabetes (hemoglobin A1c
[HbA1C] >8.0%), or evidence of decompensated liver
disease. Detailed inclusion and exclusion criteria have
been described.(17) The current study also excluded those
screened with hemochromatosis-range hepatic iron con-
centration (HIC) (greater than 2 times the upper limit of
normal) in order to avoid bias in parametric correlation
analyses. The IIRON2 study was registered with the
Australia New Zealand Clinical Trials Registry (Registra-
tion no. ACTRN12610000868088). This registration
included an a priori assessment of serum adipokine levels
as a secondary endpoint (secondary endpoint 4). Written
informed consent was obtained from all participants. The
study protocol conforms to the ethical guidelines of the
1975 Declaration of Helsinki and was approved by the
human research ethics committees of the Sir Charles
Gairdner, Fremantle, and Greenslopes Private hospital.
RANDOMIZATION
Participants were randomized, using a randomiza-
tion sequence generated by the study research coordi-
nator from a computerized random number generator,
to venesection with lifestyle advice (venesection group)
or lifestyle advice alone (control group) at a ratio of 1:1
as described.(17) Allocation concealment prior to
randomization was achieved using numbered, sealed,
opaque envelopes. Assignment was performed by the
research coordinators. All subjects received dietary
advice regarding the institution of a hypocaloric diet
from an accredited dietician, and all received standard-
ized advice regarding exercise. Participants in the vene-
section group underwent two to three weekly
venesections targeting a serum ferritin of <45 ng/mL.
CLINICAL AND LABORATORY
ASSESSMENT
A thorough clinical assessment, including history and
physical examination, was performed at baseline, 3
months, and 6 months (end of study). Standard labora-
tory parameters were measured, including liver function
tests, serum triglycerides, high-density lipoprotein cho-
lesterol, free (nonesterified) fatty acids, glucose, insulin,
glycosylated hemoglobin (HbA1C), 75-g oral glucose
tolerance test, transferrin saturation, serum ferritin, and
full blood count. Hepascore, a validated serum measure
of hepatic fibrosis in NAFLD,(18) was performed at the
Western Australia state referral laboratory (Pathwest,
Queen Elizabeth II Medical Center, Nedlands, Austra-
lia). Serum cytokeratin-18 fragments were measured
using an m30 Aptosense enzyme-linked immunosor-
bent assay (ELISA) kit (Peviva, Nacka, Sweden).
Serum concentrations of adiponectin, leptin, resistin,
RBP-4, TNFa, and IL-6 were measured using a custom-
ized, multiplexed, Quantibody, ELISA array (Human
Obesity Array Q3; Raybiotech, Norcross, GA). Assays of
participant serum samples at 1:2 dilution and adipokine
control dilutions for a standard curve were performed in
quadruplicate by Jomar Life Research, Scoresby, Austra-
lia, according to the manufacturer’s instructions.
Hepcidin-25 was isolated from patient serum by solid
phase extraction and measured by liquid chromatography
quadrupole time-of-flight mass spectrometry as
described.(19-21) Quantitation was by reference to a syn-
thetic hepcidin-25 (13C18,
15N3) peptide internal standard
(Peptides International, Inc., Louisville, KY).
IMAGING STUDIES
Hepatic steatosis and HIC were measured using
noninvasive magnetic resonance imaging (MRI) meth-
ods on a 1.5T Avanto scanner (Siemens Medical Sys-
tems, Erlagen, Germany). Hepatic steatosis was
quantified as a volumetric percentage by using a vali-
dated opposed-phase–in-phase gradient echo
BRITTON ET AL. HEPATOLOGY COMMUNICATIONS, June 2018
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protocol.(22) A validated MRI method (FerriScan) was
used to determine HIC.(23)
STATISTICAL ANALYSIS
Comparison of baseline variables between groups was
performed using the two-tailed Student t test for con-
tinuous variables and Pearson’s chi-squared or Fisher’s
exact test, as appropriate, for categorical variables. Base-
line correlation analyses were performed using Pearson’s
correlation. As the dependency between adipokines and
measures of iron is unknown, bivariate correlation analy-
sis was used to detect associations. The relationships
between serum adipokine concentrations, measures of
insulin resistance, serum ferritin, and HIC, after correc-
tion for body mass index (BMI), age, and sex, were
assessed using a partial correlation analysis. The rela-
tionships between serum hepcidin and surrogates of
insulin resistance were assessed using a partial correla-
tion analysis correcting for HIC.
For each of the six adipokines, comparisons between
the venesection and control groups of the change of
serum concentration were made using a two-sided
independent-sample t test. Further analysis of these
data was performed using analysis of covariance with




Seventy-four participants were randomized in the
study.(17) This cohort was used to analyze baseline relation-
ships of measures of insulin resistance and serum adipokines
with measures of iron status. The characteristics of this
cohort are summarized inTable 1.Of these, 60 patients had
serum stored at baseline available for measurement of serum
TABLE 1. BASELINE CHARACTERISTICS OF
RANDOMIZED PARTICIPANTS
Characteristic (n 5 73) Mean (SD)
Age, years 51.3 (10.8)
Male sex (%) 43 (59%)
BMI, kg/m2 31.4 (5.0)
Waist circumference, cm 105 (13)
Diabetes (%) 13 (18%)
ALT, IU/L 72 (56)
Hepascore 0.33 (0.26)
Glucose, mmol/L 6.1 (2.1)
Serum ferritin, ng/mL 507 (442)
Transferrin saturation, % 31.6 (13.5)
Hepatic iron concentration, mmol/kg 23.0 (11.3)
Hepatic steatosis, % by volume 18.1 (10.9)
Data are presented as mean and SD except for diabetes and male
sex, for which the total number of participants and percentage of
participants are presented. A single randomized participant with
hemochromatosis-range HIC was excluded from the analysis.
Abbreviation: ALT, alanine aminotransferase.
                                                                                                                                      
FIG. 1. Patient flow diagram
for the analysis of venesection
effect on serum adipokine
concentrations.
                                                                                                                                      
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adipokine concentrations, and 51 also had serum available
from the end of the study; this latter cohort was used in the
analysis comparing the effect of venesection (n5 23) versus
control (n5 28), as shown inFig. 1. The baseline character-
istics of the participants from each randomized group with
available paired sera are outlined inTable 2. Baseline charac-
teristics, including serum adipokine concentrations, were
not significantly different between groups.
CORRELATION OF MEASURES OF
IRON LOADING WITH BASELINE
SERUM ADIPOKINE
CONCENTRATIONS
The 61 participants with available baseline serum
were assessed to evaluate the relationships between
serum adipokine concentrations with two baseline
measures of iron status, serum ferritin and HIC (Table
3). All participants had serum ferritin measured, and
HIC was available for 56 of the 60 participants. A sin-
gle participant with hemochromatosis-range HIC (99
mmol/kg) was excluded from the analysis. HIC was
corrected for steatosis percentage volume as deter-
mined by MRI in order to provide a true comparable
iron concentration in the aqueous (nonlipid) fraction
of the liver. Baseline serum hepcidin data were avail-
able for 37 of the randomized participants.
Baseline serum ferritin was not associated with serum
concentrations of any of the six adipokines. HIC, how-
ever, showed a significant positive correlation with
serum adiponectin (P 5 0.048; rho 5 10.26) (Table 2;
Fig. 2A) but not with the other five adipokines. BMI
correlated with serum leptin concentration (P < 0.0001;





(n 5 23) P Value
Age, years 51.8 (11.3) 54.0 (9.7) 0.45
Male sex 18 (64%) 14 (61%) 0.80†
BMI, kg/m2 30.9 (5.3) 31.8 (4.4) 0.52
Waist circumference, cm 103.4 (13.9) 108.5 (11.3) 0.17
Diabetes 5 (18%) 4 (17%) 1.0*
ALT, IU/L 65.0 (37.7) 81.6 (74.0) 0.31
AST, IU/L 41.8 (20.5) 47.4 (36.6) 0.49
Bilirubin, lmol/L 13.8 (5.5) 14.0 (6.5) 0.92
Alkaline phosphatase, IU/L 84.5 (19.9) 89.2 (24.8) 0.45
Albumin, mg/dL 45.0 (3) 43.5 (2.6) 0.054
CK-18, U/L 287.2 (286.9) 367.8 (322.5) 0.36
Hepascore 0.29 (0.2) 0.42 (0.3) 0.059
Triglycerides, mmol/L 1.74 (0.9) 1.63 (0.8) 0.65
HDL-cholesterol, mmol/L 1.16 (0.3) 1.07 (0.3) 0.26
Free fatty acids, mmol/L 0.32 (0.2) 0.38 (0.2) 0.28
Glucose, mmol/L 5.64 (0.8) 6.16 (2.3) 0.27
Insulin, mU/L 15.6 (12) 14.1 (6.8) 0.60
HbA1C, % 5.89 (0.7) 6.10 (1.2) 0.46
HOMA-IR 4.24 (4.1) 4.07 (2.9) 0.86
ISI 3.44 (3.4) 3.55 (2.9) 0.91
Hemoglobin, g/L 152.7 (13.7) 149.2 (12.1) 0.34
Platelet, 3 109/dL 216.7 (33.8) 231.6 (99.2) 0.46
Ferritin, ng/mL 448.1 (388.2) 587.2 (353.2) 0.19
Transferrin saturation, % 31.6 (11.1) 33.4 (14.0) 0.63
HIC, mmol/kg 22.1 (10.2) 24.6 (12.7) 0.44
Hepatic steatosis, % 17.0 (12.7) 18.0 (8.6) 0.76
Metabolic syndrome 17 (61%) 16 (70%) 0.57*
Adiponectin, ng/mL 538.4 (249.8) 471.2 (216.7) 0.32
Leptin, ng/mL 19.5 (18.8) 22.7 (14.2) 0.50
Resistin, ng/mL 7.55 (2.6) 8.01 (2.0) 0.49
RBP-4, ng/mL 42.8 (20.1) 38.4 (12.7) 0.37
TNFa, pg/mL 292.2 (395.4) 249.2 (336.6) 0.68
IL-6, pg/mL 114.9 (171.4) 114.2 (136.3) 0.99
Values presented are mean values with SD in parentheses except for diabetes, male sex, and metabolic syndrome, for which the total
number of participants and percentage of participants are presented. P values are the result of unpaired t tests unless indicated other-
wise. *Exact P value from Fisher’s exact test, †Pearson’s chi-squared test.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK-18, cytokeratin-18; HDL, high-density
lipoprotein.
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rho 5 0.585) but not with other adipokines (data not
shown). Baseline serum ferritin and HIC were corre-
lated (n5 65; rho510.41; P5 0.001).
Correlation analysis of the baseline data was
repeated for all adipokines using partial correlation
adjusting for three potential confounders: baseline age,
sex, and BMI (Table 3). This correction strengthened
the positive relationship between serum adiponectin
and HIC (P 5 0.007; rho 5 10.36). There remained
no association between HIC and the other five adipo-
kines. When also corrected for the same factors, there
was no significant correlation between serum ferritin
and the six adipokines. An analysis of the correlation
between adiponectin and HIC in nondiabetics and
particularly in diabetics was limited by sample size. In
nondiabetics, there was no significant correlation
between adiponectin and HIC (n 5 49; rho 5 10.21;
P 5 0.15); however, after correction for age, sex, and
BMI, a partial correlation remained significant
(degrees of freedom 5 43; rho510.33; P5 0.0496).
CORRELATION OF HIC WITH
MEASURES OF INSULIN
RESISTANCE
We next sought to determine whether the associa-
tion between HIC and adiponectin was an isolated
finding or whether HIC is associated with measures of
insulin resistance. We found that HIC negatively cor-
related with six surrogates of insulin resistance relating
to different sites of insulin action. These were adipose
tissue insulin resistance (Adipo-IR),(24) percentage
hepatic steatosis, serum insulin, serum glucose,
homeostatic model assessment of insulin resistance
TABLE 3. CORRELATION BETWEEN BASELINE















Adiponectin rho 20.06 10.26 10.02 10.36
P 0.67 0.048* 0.90 0.007*
Leptin rho 20.20 20.20 20.01 20.12
P 0.13 0.13 0.92 0.38
Resistin rho 20.01 20.04 10.10 10.05
P 0.93 0.77 0.46 0.73
RBP-4 rho 10.05 10.11 10.07 10.14
P 0.68 0.44 0.60 0.31
TNFa rho 10.07 20.04 10.10 20.02
P 0.58 0.79 0.45 0.90
IL-6 rho 10.07 20.09 10.06 20.10
P 0.59 0.50 0.65 0.46
*P < 0.05.
Abbreviation: df, degrees of freedom.
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FIG. 2. Relationships between HIC and insulin sensitivity. HIC and (A) adiponectin, (B) Adipo-IR, (C) percentage hepatic steatosis,
(D) HOMA-IR, (E) HbA1C, (F) insulin sensitivity index. Abbreviation: Adipo-IR, adipose tissue insulin resistance.
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(HOMA-IR),(25) and HbA1C (Table 4; Fig. 2B-E).
Furthermore, the insulin sensitivity index (ISI)(26) was
significantly positively correlated with HIC (Table 4;
Fig. 2F). After correction for age, sex, and BMI by
partial correlation, all associations remained significant
except for adipose tissue insulin resistance (Table 4).
To determine whether insulin might mediate hepci-
din response, we analyzed the relationships between
hepcidin and the seven surrogates for insulin resis-
tance, using a partial correlation analysis correcting for
HIC (Table 4). We found that serum insulin and
serum hepcidin levels positively correlated (degrees of
freedom 5 29; rho 5 10.37; P 5 0.04). However,
there were no significant relationships between serum





Subjects in the venesection group underwent a
median of 7 venesections (range 2-19). This is
roughly equivalent to 1.58 g of iron (range 0.45-4.28
g).(27) Change in BMI during the study did not differ
between groups (control group, –0.67 kg/m2 versus
venesection group, 10.25 kg/m2; P 5 0.08, Student t
test). BMI, serum triglycerides, high-density lipopro-
tein cholesterol, low-density lipoprotein cholesterol,
HOMA-IR, and ISI were not significantly different
between groups at the end of the study.
Serum adipokine concentrations did not signifi-
cantly change between baseline and 6 months for each
of the six adipokines in each group except for a 69 pg/
mL (28%) rise in serum TNFa in the venesection
group (P 5 0.04). When comparing the difference in
absolute change of serum concentration for each adi-
pokine between the control and venesection groups,
there were no significant differences (Fig. 3). An anal-
ysis of covariance was performed correcting for baseline
BMI, age, and sex, and no significant differences
between groups were observed for each of the six adi-
pokines (data not shown).









n rho P df rho P df rho P
Adipo-IR 62 20.26 0.045* 57 20.23 0.08 29 10.14 0.46
Steatosis (%) 65 20.28 0.03* 60 20.28 0.03* 29 10.09 0.63
Insulin 65 20.26 0.04* 60 20.28 0.03* 29 10.37 0.04*
FFAs 62 20.21 0.10 57 20.14 0.29 29 20.34 0.06
Glucose 65 20.31 0.01* 60 20.26 0.04* 29 20.12 0.53
HOMA-IR 65 20.31 0.01* 60 20.30 0.02* 29 10.30 0.10
HbA1C 64 20.36 0.003* 59 20.31 0.01* 29 10.09 0.63
ISI 59 10.30 0.02* 54 10.28 0.04* 24 10.05 0.80
*P < 0.05
Abbreviations: Adipo-IR, adipose tissue insulin resistance; df, degrees of freedom; FFA, free fatty acid.
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FIG. 3. Change in serum adipokine concentrations over 6
months. Mean change is represented as a percentage of the base-
line mean for each adipokine. No significant differences were
observed for each adipokine between the control (n 5 28) and
venesection groups (n 5 23). Values represented are mean abso-
lute change in serum adipokine concentration with error bars to
represent SEM. Measured serum concentrations of TNFa and
IL-6 were below the lower limit of detection of the assays in 11
(of 102) and 23 (of 102) samples, respectively. In these instances,
the lower limit of detection value was used for statistical analysis.
An analysis in which 0 values were used instead of the lower
limit of detection values did not substantially alter the results
(data not shown).
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Discussion
In this prospective, randomized, controlled clinical
trial, we showed that venesection does not alter the serum
concentrations of six key adipokines in participants with
NAFLD. To our surprise, however, we demonstrated a
significant positive relationship between HIC and serum
adiponectin concentration in this cohort. This observa-
tion was strengthened further after correction for age,
sex, and BMI. Furthermore, we showed that HIC nega-
tively correlated with multiple measures of insulin resis-
tance. We looked at eight surrogate measures of insulin
resistance and their relationship to iron. In all cases
except for free fatty acids, a significant relationship was
found associating enhanced insulin sensitivity with
increasing HIC. These data suggest that HIC inversely
predicts insulin resistance in the periphery (adipose tissue
and skeletal muscle) as well as within the liver.
Notably, in keeping with our findings, a cross-
sectional study of 80 Italian patients with biopsy-proven
NAFLD found that the oral glucose sensitivity index
increased with increasing HIC.(28) Furthermore, a
recently published, randomized, controlled study by
Laine et al.(16) of 274 participants with dysmetabolic iron
overload and significantly elevated HIC (>50 mmol/kg)
found that venesection was associated with significantly
increased serum insulin and HOMA-IR scores over
time. We found no difference between groups in
HOMA-IR scores, ISI, or change in HOMA-IR or ISI
over time.(17) This remained the case in subgroup analy-
ses of patients with and without diabetes (data not
shown). Although we did not find that venesection
altered insulin resistance, the longer duration of venesec-
tion (12 months versus 6 months) and higher baseline
HIC in the Laine et al. study may account for the change
in insulin resistance in that study. It is therefore worth
considering that there may be subgroups of patients with
NAFLD that may develop altered adipokine concentra-
tions in response to venesection, possibly over a longer
duration of treatment.
Our findings add weight to the possibility of a causal
relationship between iron and insulin sensitivity in
individuals with NAFLD. These results suggest that
hepatic iron loading below the hemochromatosis range
(less than 2 times the upper limit of normal, normal
range 3-33 mmol/kg(29)) may actually be beneficial in
terms of insulin sensitivity. In contrast, the association
between excess hepatic iron seen in hemochromatosis
and insulin resistance and diabetes is well estab-
lished.(6) Pathologic iron overload from hereditary
hemochromatosis can cause diabetes through both
insulin deficiency from beta cell loss in the pancreas as
well as insulin resistance.(6) Our data, coupled with
these observed relationships between hemochromatosis
and insulin resistance, suggest that a “sweet-spot” of
HIC for maximal insulin sensitivity exists, above and
below which increased insulin resistance is observed.
An alternative explanation for the relationship
between HIC and insulin sensitivity is that insulin or
some aspect of insulin resistance might regulate iron
homeostasis. To explore this possibility further, we
looked at serum hepcidin concentrations and their
relationship to our eight measures of insulin sensitivity.
Hepcidin is the key regulator of systemic iron absorp-
tion through its effect on small bowel enterocyte iron
export.(30,31) Hepcidin is predominantly produced by
hepatocytes and is transcriptionally regulated by a
number of factors, including hepatic iron.(30,31) As
such, we examined the markers of insulin resistance in
relation to hepcidin after correction for HIC. We
found that serum hepcidin levels positively correlated
with serum insulin. This could indicate that insulin
signaling may play a role in hepcidin regulation
whereby insulin resistance leads to reduced intestinal
iron absorption. However, as the other measures of
insulin resistance were not associated with serum hep-
cidin levels, a direct link would seem unlikely.
We found that serum concentrations of the insulin-
sensitizing adipokine adiponectin positively correlate
with HIC. This may in part explain the relationship
between iron and insulin sensitivity in this cohort. How-
ever, adipokines, by definition, are cytokines that are syn-
thesized in adipose tissue, and therefore adipocyte (or
adipose tissue) iron concentrations are likely to be most
important with respect to iron–adipokine interactions.
Indeed, HIC may not be an accurate surrogate mea-
sure of adipose tissue iron. Rodent data have shown that
a high-fat diet leads to a redistribution of iron from the
liver to adipose tissue with a 4-fold increase in adipocyte
iron concentration and a 2-fold reduction in HIC.(32)
Human studies demonstrate that obesity is associated
not only with iron deficiency but paradoxically also with
increased subcutaneous and visceral adipose tissue
iron.(33-35) Furthermore, increased adipocyte iron lead-
ing to a reduction in adiponectin expression has been
demonstrated in a variety of mouse and adipocyte cul-
ture models.(9) Taken together, it may be possible in
NAFLD that iron redistributes from the liver to adipose
tissue, thus contributing to insulin resistance and a
reduction in serum adiponectin.
In this study, we measured HIC as a well-validated
surrogate for total body iron stores.(36) We corrected
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HIC for percentage steatosis volume in order to give a
truer more physiologically relevant HIC that is reflec-
tive of iron concentration in the aqueous (nonlipid)
fraction of the liver. By doing this, we demonstrated
that it is not simply HIC dilution by lipid that errone-
ously explains the relationships among iron, steatosis,
and other measures of insulin resistance. It should be
noted that this HIC correction is a conservative
approach to the data that weakens the associations
observed compared to when uncorrected HIC is used
(data not shown).
Contrary to our findings, a number of other studies
have indicated a positive association between serum adi-
ponectin and measures of human iron stores.(9,37,38)
These studies may be limited by the choice of surrogate
for HIC. In those three studies, inverse correlations
were noted between serum ferritin and serum adiponec-
tin; however, this only reached statistical significance in
two of the studies.(9,37) These are interesting observa-
tions that were not seen in our cohort. Although serum
ferritin undoubtedly correlates with HIC, it is clearly an
imprecise measure of HIC. Our data showed that
despite strong statistical significance (P < 0.001), the
association itself was not strong (r2 5 0.17), indicating
that only 17% of the variance in serum ferritin is attrib-
utable to HIC. Ryan et al.(38) have recently reported an
inverse association between liver iron and serum adipo-
nectin. However, the MRI T2* values, used as an
inverse surrogate for HIC, were not corrected for vol-
ume of hepatic steatosis. In addition, there may have
been a greater degree of liver injury in the Ryan et al.
cohort, with 35.3% of individuals reported as having tis-
sue elastography measurements indicative of bridging
fibrosis or cirrhosis. These factors may, in part, explain
the disparity between the two cohorts.
A weakness of our study is that it presupposes that
venesection mobilizes adipose tissue iron as it does for
other tissues. Although it is increasingly clear that adi-
pocytes use much of the iron metabolism apparatus
that is used in other tissues, such as transferrin receptor
1, hepcidin, and ferroportin, we are not aware of any
human data that have addressed the degree to which
adipose tissue iron is mobilized by venesection.(9,39)
Another limitation of our study is the lack of liver his-
tology. It is likely that there was a degree of heteroge-
neity of liver injury among participants studied. In
addition, the lack of liver histology does not allow for
determination of the relative distribution of iron
between hepatocytes and reticuloendothelial cells. This
may be critical to iron’s impact within the liver as retic-
uloendothelial iron has been shown to be associated
with apoptosis and a greater risk of hepatocellular bal-
looning, steatohepatitis, and advanced fibrosis in
humans with NAFLD.(40,41)
A strength of this study is that it represents an a priori
assessment as part of a randomized controlled trial. Our
study failed to demonstrate any effect of venesection on
serum concentrations of the six adipokines studied. It is
possible that our study may be underpowered for some
of the adipokines as these were secondary endpoints for
which the study was not prospectively powered.
In conclusion, we found a lack of effect of venesec-
tion on serum concentrations of six important adipo-
kines in patients with NAFLD. However, we
demonstrated significant correlations between hepatic
iron, serum adiponectin, and multiple surrogate mea-
sures of insulin sensitivity. The causality of these rela-
tionships remains uncertain. Mechanistic explanations
for the relationships between iron metabolism and
insulin resistance are targets for future studies.
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